Colchester Hospital University NHS Foundation Trust

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Retrieved on: 
Wednesday, July 6, 2022
Adenocarcinoma, Patient, Immunosuppression, GLOBE, Cancer, Company, Gastrointestinal cancer, Neoplasm, IND, Quality of life, Prostate cancer, Nature, Colorectal cancer, Therapy, PRTG, Achievement, A2A, Rockefeller University, LLC, Cornell University, Immunotherapy, LPC, Twitter, Eastern Time Zone, Research, Acquisition, LinkedIn, CEO, Novartis, Harvard Medical School, Nanoparticle, Weill Cornell Medicine, Survival, NASDAQ, Board, Leadership, News, Liposome, L-Ribonucleic acid aptamer, Adenosine, International, Evaluation, Sale, TME, A2B, EVP, Lists of companies, Colchester Hospital University NHS Foundation Trust, Tumor microenvironment, Credit Suisse, Conference, Vaccine, Management, Pharmaceutical industry, Director, Venture, Taro (river)

WESTPORT, Conn., July 06, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, announced that it has signed an agreement to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists. Under the terms of the agreement, Portage will acquire Tarus in exchange for 2,425,999 PRTG shares along with the assumption of $3 million of liabilities. Additionally, payments of up to $32M in Portage shares or cash would be triggered upon achievement of future development and sales milestones. As a result of the transaction, Portage acquires four best-in-class assets targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.

Key Points: 
  • As a result of the transaction, Portage acquires four best-in-class assets targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.
  • Furthermore, the potential promise of the adenosine assets, coupled with Portages highly experienced development team, underscores the rationale to partner these best-in-class assets with Portage.
  • The new assets acquired from Tarus Therapeutics include:
    TT-10 (now PORT-6): an adenosine receptor type 2A (A2A) inhibitor to treat solid tumors.
  • For more information, please visit www.portagebiotech.com , follow us on Twitter at @PortageBiotech or find us on LinkedIn atPortage Biotech Inc.

NuvoAir Launches Remote Asthma Service to Support NHS with Faster Diagnosis and Treatment

Retrieved on: 
Wednesday, May 25, 2022
Biotechnology, Medical Devices, Hospitals, Health, Clinical Trials, NHS, Spirometry, Death, Attack, Ageing, NHS trust, Asthma, Multimedia, Patient, Degenerative disease, COPD, University Hospitals of Leicester NHS Trust, Solution, University Hospitals Cleveland Medical Center, Portsmouth Hospitals University NHS Trust, Awareness, Mortality, Lancet, Royal Brompton Hospital, Colchester Hospital University NHS Foundation Trust, AOS, Air Next, COVID, Diagnosis, CEO, Hospital, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220523005860/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220523005860/en/
    Since 2017, NuvoAir has worked with over 40 NHS trusts, enabling NHS services to manage nearly 5,000 respiratory patients.
  • May is Asthma Awareness Month and efforts are underway to educate the public on the status of asthma in the UK, where asthma deaths are amongst the worst in Europe.
  • The NuvoAir Asthma Service will potentially improve access to this aspect of asthma care for people with asthma, leading to fewer asthma symptoms and attacks, says Professor Peter Bradding from University Hospitals of Leicester NHS Trust.
  • NuvoAir Founder and CEO, Lorenzo Consoli shares, We are excited to partner with the NHS and forward-looking clinicians to redesign new care pathways for people with asthma.

U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

Retrieved on: 
Thursday, November 18, 2021
Patient, HLHS, Congenital heart defect, Health status of Asian Americans, Security (finance), Advocate, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Review, Cell, Disorder, Ageing, MSC, Hypoplastic left heart syndrome, Trial of the century, Frailty, Company, Forward-looking statement, Microsoft, MD, Doctor of Philosophy, Weight gain, U.S. Securities and Exchange Commission, Intussusception (medical disorder), Program, Principal, Lung, Goal, Metabolic syndrome, Northwest Hospital & Medical Center, National Institute, NHLBI, GLOBE, Phase II, Adult, National Heart, Lung, and Blood Institute, Terminology, Patent, OH, Children's Hospital Los Angeles, Hospital, FDA, Colchester Hospital University NHS Foundation Trust, Bone marrow, RPD, Intention, NASDAQ, PRV, Food, Pharmaceutical industry

Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.

Key Points: 
  • Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.
  • We are encouraged by our Phase 1 clinical data, and the progress being made in the ongoing Phase 2 trial.
  • Lomecel-B represents a unique cell therapy approach that could potentially be administered at the same time as surgery in these critically impacted infants.
  • Longeveron recently reported clinical results from its safety-focused Phase I clinical study of Lomecel-B in HLHS patients.

VitalHub Announces Licensing Deal with East Suffolk and North Essex NHS Foundation Trust

Retrieved on: 
Tuesday, November 17, 2020
National Health Service, Counties of England, NHS Foundation Trusts, England, East Suffolk and North Essex NHS Foundation Trust, Ipswich, Colchester Hospital University NHS Foundation Trust, Keogh Review

TORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSXV: VHI) is pleased to announce an expansion licensing transaction of newly-acquired subsidiary Intouch with Healths (Intouch) suite of patient flow and operational visibility solutions to East Suffolk and North Essex NHS Foundation Trust (the Trust or ESNEFT).

Key Points: 
  • TORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the Company or VitalHub) (TSXV: VHI) is pleased to announce an expansion licensing transaction of newly-acquired subsidiary Intouch with Healths (Intouch) suite of patient flow and operational visibility solutions to East Suffolk and North Essex NHS Foundation Trust (the Trust or ESNEFT).
  • East Suffolk and North Essex NHS Foundation Trust provides hospital and community health care services for Colchester, Ipswich and local areas, including Aldeburgh, Clacton, Halstead, Harwich and Felixstowe community hospitals and Bluebird Lodge near Ipswich, and is the largest NHS organization in the region.
  • The Trust is following the lead of the Worcestershire Acute Hospitals NHS Trust, who have pre-assessed 100% of their patients remotely since March.
  • East Suffolk and North Essex NHS Foundation Trust delivers hospital and community healthcare services for Colchester, Ipswich, and surrounding areas as the largest NHS organization in the region.